BackSummary
Abbott Laboratories reported Q1 2026 results with $11.2B sales up 7.8% reported and 3.7% comparable, GAAP EPS $0.61, adjusted EPS $1.15 up 6%, completed Exact Sciences acquisition, and raised full-year guidance.
Key takeaways
- Q1 sales $11,164M, +7.8% reported, +3.7% comparable vs Q1 2025.
- GAAP diluted EPS $0.61; adjusted $1.15, +6% growth.
- Completed Exact Sciences acquisition on March 23, 2026, adding oncology diagnostics.
- FY2026 guidance: comparable sales +6.5%-7.5%, adjusted EPS $5.38-$5.58 incl. $0.20 dilution.
- Q2 2026 adjusted EPS guidance $1.25-$1.31.
- Declared $0.63/share dividend, payable May 15, 2026.